AstraZeneca gets a green light on Imfinzi for small-cell lung cancer — setting the stage for a battle with Roche's Tecentriq
The standard-of-care for small-cell lung cancer (SCLC) for decades was platinum-based chemotherapy, but that paradigm shifted in 2018, with the approval of Bristol Myers Squibb’s checkpoint inhibitor Opdivo in the second-line setting. Since then, a slate of immunotherapies have secured SCLC approvals, and the latest is AstraZeneca’s flagship Imfinzi, which was approved on Monday in combination with standard chemotherapy as the first line of defense in extensive-stage SCLC patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.